Erik Nilsson1, Alessandro Gasparini2, Johan Ärnlöv3, Hairong Xu4, Karin M Henriksson3, Josef Coresh5, Morgan E Grams5, Juan Jesus Carrero6. 1. Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; Department of Internal Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden; Division of Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. 2. Department of Health Sciences, University of Leicester, United Kingdom. 3. Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. 4. AstraZeneca, Gaithersburg, MD, USA. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet, Sweden. Electronic address: juan.jesus.carrero@ki.se.
Abstract
BACKGROUND: Hypo- and hyperkalemia in clinical settings are insufficiently characterized and large-scale data from Europe lacking. We studied incidence and determinants of these abnormalities in a large Swedish healthcare system. METHODS: Observational study from the Stockholm CREAtinine Measurements project, including adult individuals from Stockholm accessing healthcare in 2009 (n=364,955). Over 3-years, we estimated the incidence of hypokalemia, defined as potassium<3.5mmol/L, hyperkalemia, defined as potassium>5mmol/L, and moderate/severe hyperkalemia, defined as potassium>5.5mmol/L. Kidney function was assessed by estimated glomerular filtration rate (eGFR). RESULTS: Of 364,955 participants, 69.4% had 1-2 potassium tests, 16.7% had 3-4 tests and the remaining 13.9% had >4potassiumtests/year. Hypokalemia occurred in 49,662 (13.6%) individuals, with 33% recurrence. Hyperkalemia occurred in 25,461 (7%) individuals, with 35.7% recurrence. Moderate/severe hyperkalemia occurred in 9059 (2.5%) with 28% recurrence. The frequency of potassium testing was an important determinant of dyskalemia risk. The incidence proportion of hyperkalemia was higher in the presence of diabetes, lower eGFR, myocardial infarction, heart failure (HF), or use of renin angiotensin-aldosterone system inhibitors (RAASi). In adjusted analyses, women and use of loop/thiazide diuretics were associated with lower hyperkalemia risk. Older age, lower eGFR, diabetes, HF and use of RAASi were associated with higher hyperkalemia risk. On the other hand, women, younger age, higher eGFR and baseline use of diuretics were associated with higher hypokalemia risk. CONCLUSION: Hypo- and hyperkalemia are common in healthcare. Optimal RAASi and diuretics use and careful potassium monitoring in the presence of certain comorbidities, especially lower eGFR, is advocated.
BACKGROUND: Hypo- and hyperkalemia in clinical settings are insufficiently characterized and large-scale data from Europe lacking. We studied incidence and determinants of these abnormalities in a large Swedish healthcare system. METHODS: Observational study from the Stockholm CREAtinine Measurements project, including adult individuals from Stockholm accessing healthcare in 2009 (n=364,955). Over 3-years, we estimated the incidence of hypokalemia, defined as potassium<3.5mmol/L, hyperkalemia, defined as potassium>5mmol/L, and moderate/severe hyperkalemia, defined as potassium>5.5mmol/L. Kidney function was assessed by estimated glomerular filtration rate (eGFR). RESULTS: Of 364,955 participants, 69.4% had 1-2 potassium tests, 16.7% had 3-4 tests and the remaining 13.9% had >4potassiumtests/year. Hypokalemia occurred in 49,662 (13.6%) individuals, with 33% recurrence. Hyperkalemia occurred in 25,461 (7%) individuals, with 35.7% recurrence. Moderate/severe hyperkalemia occurred in 9059 (2.5%) with 28% recurrence. The frequency of potassium testing was an important determinant of dyskalemia risk. The incidence proportion of hyperkalemia was higher in the presence of diabetes, lower eGFR, myocardial infarction, heart failure (HF), or use of renin angiotensin-aldosterone system inhibitors (RAASi). In adjusted analyses, women and use of loop/thiazide diuretics were associated with lower hyperkalemia risk. Older age, lower eGFR, diabetes, HF and use of RAASi were associated with higher hyperkalemia risk. On the other hand, women, younger age, higher eGFR and baseline use of diuretics were associated with higher hypokalemia risk. CONCLUSION: Hypo- and hyperkalemia are common in healthcare. Optimal RAASi and diuretics use and careful potassium monitoring in the presence of certain comorbidities, especially lower eGFR, is advocated.
Authors: Erik Nilsson; Pietro De Deco; Marco Trevisan; Rino Bellocco; Bengt Lindholm; Lars H Lund; Josef Coresh; Juan J Carrero Journal: Eur Heart J Qual Care Clin Outcomes Date: 2018-10-01
Authors: Emily B Schroeder; John L Adams; Michel Chonchol; Gregory A Nichols; Patrick J O'Connor; J David Powers; Julie A Schmittdiel; Susan M Shetterly; John F Steiner Journal: J Gen Intern Med Date: 2020-04-16 Impact factor: 5.128
Authors: Gregory L Hundemer; Robert Talarico; Navdeep Tangri; Silvia J Leon; Sarah E Bota; Emily Rhodes; Greg A Knoll; Manish M Sood Journal: Clin J Am Soc Nephrol Date: 2021-02-19 Impact factor: 8.237
Authors: Sriram Sriperumbuduri; Eric McArthur; Gregory L Hundemer; Mark Canney; Navdeep Tangri; Silvia J Leon; Sara Bota; Ann Bugeja; Ayub Akbari; Greg Knoll; Manish M Sood Journal: Can J Kidney Health Dis Date: 2021-05-27
Authors: Laura Horne; Akhtar Ashfaq; Sharon MacLachlan; Marvin Sinsakul; Lei Qin; Robert LoCasale; James B Wetmore Journal: BMC Nephrol Date: 2019-03-06 Impact factor: 2.388